BridgeBio Oncology Therapeutics, Inc. (BBOT)
Health Care · Oncology therapeutics / RAS and PI3K pathway inhibitors · Nasdaq
BridgeBio Oncology is advancing next-generation small-molecule inhibitors of RAS and PI3K pathways for previously untreatable solid tumors including KRAS-driven lung and pancreatic cancers.
What BridgeBio Oncology Therapeutics, Inc. does
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small-molecule therapeutics targeting RAS and Phosphoinositide 3-kinase (PI3K) pathways for patients with solid tumors. The company is advancing three lead product candidates: BBO-8520 (KRAS G12C inhibitor for NSCLC), BBO-11818 (pan-KRAS inhibitor for KRAS-mutant tumors), and BBO-10203 (RAS-PI3K inhibitor for breast cancer and other solid tumors). With no approved products and no revenue to date, the company is currently in Phase 1 clinical trials with multiple ongoing studies.
Themes: ["RAS inhibitors / KRAS-targeted therapeutics","PI3K pathway inhibition","Oncology / cancer therapeutics","Small-molecule inhibitors","Non-small cell lung cancer (NSCLC)","Pancreatic cancer","Colorectal cancer","Breast cancer","Clinical-stage biotech"]
Fundamentals
- Price$8.32 as of 2026-07-10 close
- Market cap$666M as of 2026-07-13
- 1-year return-22.0% as of 2026-07-10 close
- P/E141.28 as of 2026-07-13
- ROE+2.5% as of 2026-07-13
- Debt / equity0.00 as of 2026-07-13
- Beta0.88 as of 2026-07-13
Key risks (from latest filing)
["Limited operating history with no approved products, no revenue generation, and no completed clinical trials; dependency on achieving development and regulatory approval milestones for product candidates to generate future revenue and achieve profitability.","Clinical trials may fail to adequately demonstrate safety and efficacy; preclinical and early clinical data may not predict success in later trials, and regulatory approval is lengthy, unpredictable, and not guaranteed by the FDA or comparable authorities.","Dependency on third-party manufacturers for preclinical, clinical, and commercial drug supplies; inadequate supply, manufacturing delays, or cost issues could delay or prevent product commercialization."]
Competitors & peers
- Array BioPharma (BFAM)
- Calithera Biosciences
- Gritstone bio
- Mirati Therapeutics (MRTX)
- Ayala Pharmaceuticals
- Revolution Medicines
- Arcus Biosciences
- Roche/Genentech
Fundamentals: Finnhub, as of 2026-07-13. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.